1. Home
  2. BXC vs NTLA Comparison

BXC vs NTLA Comparison

Compare BXC & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BXC
  • NTLA
  • Stock Information
  • Founded
  • BXC 2004
  • NTLA 2014
  • Country
  • BXC United States
  • NTLA United States
  • Employees
  • BXC N/A
  • NTLA N/A
  • Industry
  • BXC Wholesale Distributors
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • BXC Consumer Discretionary
  • NTLA Health Care
  • Exchange
  • BXC Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • BXC 869.2M
  • NTLA 959.4M
  • IPO Year
  • BXC 2004
  • NTLA 2016
  • Fundamental
  • Price
  • BXC $82.41
  • NTLA $12.17
  • Analyst Decision
  • BXC Strong Buy
  • NTLA Buy
  • Analyst Count
  • BXC 4
  • NTLA 18
  • Target Price
  • BXC $127.75
  • NTLA $50.53
  • AVG Volume (30 Days)
  • BXC 70.3K
  • NTLA 3.1M
  • Earning Date
  • BXC 02-18-2025
  • NTLA 02-27-2025
  • Dividend Yield
  • BXC N/A
  • NTLA N/A
  • EPS Growth
  • BXC 14.84
  • NTLA N/A
  • EPS
  • BXC 6.19
  • NTLA N/A
  • Revenue
  • BXC $2,952,532,000.00
  • NTLA $43,086,000.00
  • Revenue This Year
  • BXC N/A
  • NTLA $50.68
  • Revenue Next Year
  • BXC $4.41
  • NTLA N/A
  • P/E Ratio
  • BXC $13.33
  • NTLA N/A
  • Revenue Growth
  • BXC N/A
  • NTLA N/A
  • 52 Week Low
  • BXC $82.23
  • NTLA $8.96
  • 52 Week High
  • BXC $134.79
  • NTLA $34.87
  • Technical
  • Relative Strength Index (RSI)
  • BXC 22.63
  • NTLA 61.74
  • Support Level
  • BXC $86.21
  • NTLA $8.96
  • Resistance Level
  • BXC $103.10
  • NTLA $12.84
  • Average True Range (ATR)
  • BXC 3.66
  • NTLA 0.73
  • MACD
  • BXC -1.99
  • NTLA 0.39
  • Stochastic Oscillator
  • BXC 0.69
  • NTLA 82.73

About BXC Bluelinx Holdings Inc.

BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: